For AYA Survivors of Hodgkin/Non-Hodgkin Lymphoma

EAQ211 Available Through ECOG-ACRIN Cancer Research Group

Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma

May 2021

Patient Population
See Section 3 for Complete Eligibility Details

Selection of Sites: NCORP sites

Selection of Participants:
• Must be ≥ 18 years of age at the time of registration
• Must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin or Non-Hodgkin lymphoma
• Must have completed therapy (with a complete response, per clinician determination) at the time of registration
• Patient’s last date of prior systemic therapy for first primary diagnosis for Hodgkin/Non-Hodgkin lymphoma must have been within 1 year prior to registration
  ◦ Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, IV/oral targeted medications, or radiation, and administered via a clinical trial or standard approach
• Must have an ECOG PS 0-3
• Must be English speaking (note: sites cannot translate the associated QOL forms)
• Must not be receiving active therapy for Hodgkin/Non-Hodgkin lymphoma
• Must have internet access through a computer, tablet, or smartphone
• Must have an email address

Methodology Plan
See Section 5 for Methodology Details

• This is a longitudinal study of 2,000 AYA lymphoma survivors recruited within 1 year following completion of treatment for Hodgkin/Non-Hodgkin lymphoma
• Blood specimens will be collected at baseline and subsequently every 6 months over 2 years (at 6, 12, 18, and 24 months; +/- 14 days)
• Patient-reported outcome measures will be administered via online/mobile survey at the same time points (at 6, 12, 18 and 24 months; +/- 14 days)
  ◇ Information from survey data will be captured via
  ◦ EASEE-PRO
  ◦ Health-Related QOL (including physical well-being) will be assessed via the PROMIS-29 v2
  ◦ Symptoms and late effects will be assessed via the self-administered Charlson Co-morbidity index and the NCI Common Toxicity Criteria for AEs
  ◦ Social-environmental risk factors will be assessed by:
    ◦ The Accountable Health Communities Health-Related Social Needs Screening Tool
    ◦ The Attachment Subscale of the Social Provisions Scale
    ◦ The Behavioral Risk Factor Surveillance System Adverse Childhood Experiences module
    ◦ The Perceived Discrimination Scale
  ◦ Individual resilience factors will be assessed by:
    ◦ DUFS
    ◦ Mental Health Continuum Short Form
    ◦ PROMIS Short Form
    ◦ Indicators of socioeconomic status, assets, and employment/school status will be collected via survey

Patient Enrollment
All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org/open

Protocol Information

Please Enroll Your Eligible Patients!
Surveys entered via Easte-Pro; blood sample to lab for processing

- Eligibility
  - Continue to monitor for DFS and study failure
  - Share OR code to study after
  - Be eligible for participation in a research study
  - Inform potentially eligible subjects that they may be eligible for registration, survey administration, and blood draws to study registration, survey administration, and consent will be obtained at a later time and prior to DFS confirmed.

If DFS confirmed:
- Eligibility
  - Confirm DFS status
  - Post Treatment CI baseline
  - Within one year following completion of last systemic therapy (chemo)
  - Register to study
  - Consent to study
  - OR code to study
  - Inform eligible subject of study

Last systemic therapy (chemo)